EXPLORE!

EMA grants marketing authorization to Alkindi for treatment of primary adrenal insufficiency

  736 Views

#Internal Medicine  #Pediatrics 

eMediNexus    19 December 2017

The European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a paediatric-use marketing authorisation for Alkindi (hydrocortisone) for the treatment of primary adrenal insufficiency, a rare hormonal disorder, in infants, children and adolescents.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.